We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.
- Authors
Kodama, Kenichiro; Kawaoka, Tomokazu; Kosaka, Masanari; Johira, Yusuke; Shirane, Yuki; Miura, Ryoichi; Yano, Shigeki; Murakami, Serami; Amioka, Kei; Naruto, Kensuke; Ando, Yuwa; Kosaka, Yumi; Uchikawa, Shinsuke; Fujino, Hatsue; Nakahara, Takashi; Murakami, Eisuke; Okamoto, Wataru; Yamauchi, Masami; Miki, Daiki; Imamura, Michio
- Abstract
<bold>Background: </bold>Intrahepatic cholangiocarcinoma is the second most common primary cancer of the liver. It is highly malignant and its prognosis is very poor. Although there have been various reports on the effects of calcium channel blockers on cancer, the effects of calcium channel blockers on intrahepatic cholangiocarcinoma have not been reported so far.<bold>Methods: </bold>Seventy-nine patients diagnosed with intrahepatic cholangiocarcinoma by hepatectomy between January 2002 and May 2019 were retrospectively evaluated. We compared prognosis and time to recurrence between patients treated with calcium channel blockers (CCBs) (n = 29) and those not treated with CCBs (n = 50). Propensity score matching reduced confounding biases and yielded 25 matched patient pairs. Survival between groups was compared using Kaplan-Meier analyses, logrank tests, and Cox proportional hazard regression models.<bold>Results: </bold>Overall survival and recurrence-free survival of the CCBs group were significantly longer than those of the non-CCBs group OS in the original cohort and matched cohort (98 months vs 45 months, p = 0.010; 96 months vs 22 months, p = 0.020, respectively). Multivariate analyses showed that CCBs treatment was independently associated with overall survival (HR, 0.37; 95% CI 0.16-0.85; p = 0.019) and recurrence-free survival (HR, 0.39; 95% CI 0.17-0.90; p = 0.020) in the original cohort and matched cohort, respectively.<bold>Conclusion: </bold>CCBs treatment might improve prognosis of patients with intrahepatic cholangiocarcinoma.
- Subjects
BILE duct surgery; BILE duct tumors; CHOLANGIOCARCINOMA; CALCIUM antagonists; RETROSPECTIVE studies; PROGNOSIS; CANCER relapse; TREATMENT effectiveness; BILE ducts; HEPATECTOMY
- Publication
Journal of Gastroenterology, 2022, Vol 57, Issue 9, p676
- ISSN
0944-1174
- Publication type
journal article
- DOI
10.1007/s00535-022-01887-3